Stock price of Transgenomic, Inc. (OTC:TBIO) looks quite unstable these days. Yesterday, it fell down 6.72% , while its traded 
volume flew up.
Historical data shows that there is not much news about TBIO lately, apart from its financial results. In any case, it looks like the company has decided to change this fact and made an announcement yesterday.
Unfortunately, the only information provided by the news was that Mr Craig Tuttle, CEO of Transgenomic, will be presenting at the Oppenheimer 22nd Annual Healthcare Conference on Dec 14, this year. Any further data on the company’s operations was not reported.
TRANSGENOMIC is a global biotechnology company providing products and services for automated high sensitivity genetic variation and mutation analysis. Last month, the company filed its quarterly report, which however, was not much inspiring.
As of September 30, cash and cash equivalents of TBIO have decreased significantly and the stockholders’ deficit was a negative value. At the same time, both the company’s net loss and accumulated deficit jumped up.[BANNER]
Transgenomic historically operated at a loss and has not consistently generated sufficient cash from operating activities to cover their operating and other cash expenses. Nevertheless, TBIO have been able to finance their operating losses through borrowings or from the issuance of additional equity.
Currently, the management believes that existing sources of liquidity are sufficient to meet expected cash needs into 2012. Though, the team claims that it may also be necessary to secure additional funding in the near future. Accordingly, TBIO may not have sufficient sources of liquidity to continue its operations indefinitely.
